Nutrafol

HQ
New York, New York, USA
255 Total Employees
Year Founded: 2014

Similar Companies Hiring

Artificial Intelligence • Big Data • Healthtech • Machine Learning • Software • Database • Analytics
37 Offices
2407 Employees
Cannabis • eCommerce • Enterprise Web • Logistics • Payments • Software • Database
New York, NY
190 Employees
Healthtech • Social Impact • Software
2 Offices
460 Employees

Nutrafol Company Stability & Growth

Updated on February 01, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for Nutrafol?

Strengths in market leadership, revenue momentum, and multi-channel expansion are accompanied by reputational and durability risks tied to regulatory scrutiny and the crowded, trend‑sensitive category. Together, these dynamics suggest a resilient growth profile with strong competitive advantages that must be sustained through compliant claims, differentiation, and disciplined execution across channels.
Positive Themes About Nutrafol
  • Strong Market Position & Advantage: The brand is described as the U.S. leader in hair growth supplements, with dominant marketplace share and the No. 1 dermatologist‑recommended positioning. Post‑acquisition scale and visibility across major channels reinforce a durable competitive edge.
  • Strong Revenue Growth: Turnover has more than doubled since the 2022 acquisition, with continued double‑digit growth signaled into 2024–2025 and strong DTC performance driven by repeat purchasers. Parent‑company updates consistently cite the brand as a key growth contributor.
  • Market Expansion: Distribution has expanded beyond DTC into specialty retail and international e‑commerce, adding Sephora, Ulta, and a China launch. High‑profile collaborations further broaden reach and mainstream awareness.
Considerations About Nutrafol
  • Weak or Declining Brand Reputation: Regulatory scrutiny of advertising claims and class‑action allegations around “clinically proven” positioning present reputational risk in a sensitive supplement category. The absence of FDA approval for supplements relative to drugs can amplify skepticism about efficacy claims.
  • Short-Term or Unsustainable Growth: Growth is expected to moderate as the brand scales in a crowded, trend‑sensitive category where sustained gains depend on differentiation and retention. Retail expansion may face broader beauty cycle and shelf productivity pressures that could temper momentum.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
AI Report
AI Report

The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.
Is This Your Company? Claim Profile